Fertility preservation in young women with epithelial ovarian cancer

Cancer

Volumn 115, Issue 18, 2009, Pages 4118-4126

  Wright, Jason D ^a,b   Shah, Monjri ^a   Mathew, Leny ^c   Burke, William M ^a,b,d   Culhane, Jennifer ^c   Goldman, Noah ^d   Schiff, Peter B ^a,b   Herzog, Thomas J ^a,b  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b NewYork Presbyterian Hospital   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d VALLEY HOSPITAL   (United States)

Author keywords

Fertility conserving surgery; Hysterectomy; Oophorectomy; Ovarian cancer

Indexed keywords

ADULT; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; EPITHELIAL OVARIAN CANCER; FEMALE; FERTILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ORGAN PRESERVATION; OVARIECTOMY; OVARY CANCER; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; SURGICAL TECHNIQUE;

ADULT; FEMALE; FERTILITY; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; HYSTERECTOMY; MIDDLE AGED; OVARIAN NEOPLASMS; OVARIECTOMY; SEER PROGRAM; TREATMENT OUTCOME;

EID: 70149084975     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24461     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
2. Trimbos JB, Parmar M, Vergote I, et al. International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant Chemotherapy in Ovarian Neoplasm trial: 2 parallel randomized phase III trials of adjuvant chemotherapy in patients with early stage ovarian carcinoma. J Natl Cancer Inst. 2003;95:105-112. (Pubitemid 36196730)
3. Trimbos JB, Vergote I, Bolis G, et al. Impact of adjuvant chemotherapy and surgical staging in early stage ovarian carcinoma: European Organization for Research and Treatment of Cancer-Adjuvant Chemotherapy in Ovarian Neoplasm trial. J Natl Cancer Inst. 2003;95:113-125. (Pubitemid 36193260)
4. Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of 2 prospective randomized trials. N Engl J Med. 1990;322:1021-1027.
5. Ahmed FY, Wiltshaw E, A'Hern RP, et al. Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol. 1996;14:2968-2975. (Pubitemid 26371455)
6. Duska LR, Chang YC, Flynn CE, et al. Epithelial ovarian carcinoma in the reproductive age group. Cancer. 1999;85:2623-2629. (Pubitemid 29272749)
7. Plaxe SC, Braly PS, Freddo JL, McClay E, Kirmani S, Howell SB. Profiles of women age 30-39 and age less than 30 with epithelial ovarian cancer. Obstet Gynecol. 1993;81(5 pt 1):651-654. (Pubitemid 23137228)
8. Smedley H, Sikora K. Age as a prognostic factor in epithelial ovarian carcinoma. Br J Obstet Gynaecol. 1985;92:839-842. (Pubitemid 16172055)
9. Swenerton KD, Hislop TG, Spinelli J, LeRiche JC, Yang N, Boyes DA. Ovarian carcinoma: a multivariate analysis of prognostic factors. Obstet Gynecol. 1985;65:264-270. (Pubitemid 15166989)
10. Massi D, Susini T, Savino L, Boddi V, Amunni G, Colafranceschi M. Epithelial ovarian tumors in the reproductive age group: age is not an independent prognostic factor. Cancer. 1996;77:1131-1136. (Pubitemid 26080904)
11. Thigpen T, Brady MF, Omura GA, et al. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer. 1993;71(2 suppl):606-614.
12. National Cancer Institute, Surveillance, Epidemiology and End Results (SEER) Program. SEER*Stat Database: Incidence- SEER 9 registries limited-use, November 2006 submission (1973-2004), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. Released April 2007, based on the November 2006 submission. Available at: http://.seer.cancer. gov. Accessed October 1, 2007.
13. National Cancer Institute, Surveillance, Epidemiology and End Results (SEER) Program. The SEER Program, Data Quality. Bethesda, Md: National Cancer Institute; 2007. Available at: http://seer.cancer.gov/about/. Accessed October 1, 2007.
14. Frey CM, McMillen MM, Cowan CD, Horm JW, Kessler LG. Representativeness of the Surveillance, Epidemiology, and End Results Program data: recent trends in cancer mortality rates. J Natl Cancer Inst. 1992;84:872-877.
15. Zanetta G, Rota SM, Lissoni A, Chiari S, Bratina G, Mangioni C. Conservative treatment followed by chemotherapy with doxorubicin and ifosfamide for cervical sarcoma botryoides in young females. Br J Cancer. 1999;80(3-4):403-406. (Pubitemid 29213192)
16. Morice P, Wicart-Poque F, Rey A, et al. Results of conservative treatment in epithelial ovarian carcinoma. Cancer. 2001;92:2412-2418. (Pubitemid 33029087)
17. Schilder JM, Thompson AM, DePriest PD, et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol. 2002;87:1-7.
18. Raspagliesi F, Fontanelli R, Paladini D, di Re EM. Conservative surgery in high-risk epithelial ovarian carcinoma. J Am Coll Surg. 1997;185:457-460. (Pubitemid 27475444)
19. Borgfeldt C, Iosif C, Masback A. Fertility-sparing surgery and outcome in fertile women with ovarian borderline tumors and epithelial invasive ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2007;134:110-114. (Pubitemid 47332804)
20. Chan JK, Teoh D, Hu JM, Shin JY, Osann K, Kapp DS. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol. 2008;109:370-376.
21. Gershenson DM. Menstrual and reproductive function after treatment with combination chemotherapy for malignant ovarian germ cell tumors. J Clin Oncol. 1988;6:270-275.
22. Whitehead E, Shalet SM, Blackledge G, Todd I, Crowther D, Beardwell CG. The effect of combination chemotherapy on ovarian function in women treated for Hodgkin's disease. Cancer. 1983;52:988-993.
23. Petrek JA, Naughton MJ, Case LD, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. J Clin Oncol. 2006;24:1045-1051.
24. Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause. 2006;13:265-279. (Pubitemid 43755881)
25. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med. 1987;316:1105-1110. (Pubitemid 17052498)
26. Cummings SR, Browner WS, Bauer D, et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med. 1998;339:733-738.
27. Rocca WA, Bower JH, Maraganore DM, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology. 2007;69:1074-1083.
28. Parker WH, Broder MS, Liu Z, Shoupe D, Farquhar C, Berek JS. Ovarian conservation at the time of hysterectomy for benign disease. Obstet Gynecol. 2005;106:219-226. (Pubitemid 41023257)
29. Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ 3rd. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol. 2006;7:821-828.
30. Cass I, Li AJ, Runowicz CD, et al. Pattern of lymph node metastases in clinically unilateral stage I invasive epithelial ovarian carcinomas. Gynecol Oncol. 2001;80:56-61. (Pubitemid 32062089)
31. Burghardt E, Girardi F, Lahousen M, Tamussino K, Stettner H. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol. 1991;40:103-106.
32. Benjamin I, Morgan MA, Rubin SC. Occult bilateral involvement in stage I epithelial ovarian cancer. Gynecol Oncol. 1999;72:288-291. (Pubitemid 29118183)